XML 43 R35.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Drug Development Segment and Reconciliation to Consolidated Net (Loss) Income Segment Operations | The table below provides information about the Company's drug development segment and includes the reconciliation to consolidated net (loss) income for the years ended December 31, 2024 and 2023, respectively (in thousands).
|  | 2024 |  |  | 2023 |
Revenue |  | $ | 3,746 |  |  | $ | 140,141 |
Less: |  |  |  |  |  |
Clinical expense |  |  | 8,085 |  |  |  | 15,452 |
Preclinical expense |  |  | 2,420 |  |  |  | 1,740 |
Chemistry, manufacturing, and controls |  |  | 7,161 |  |  |  | 3,273 |
Selling, general, and administrative |  |  | 14,458 |  |  |  | 20,920 |
Income tax expense |  |  | 151 |  |  |  | 138 |
Interest expense |  |  | 828 |  |  |  | 3,130 |
Plus: |  |  |  |  |  |
Interest income |  |  | 4,291 |  |  |  | 3,954 |
Other segment (income) expense (1) |  |  | (3,778 | ) |  |  | 32,401 |
Segment net (loss) income |  |  | (21,288 | ) |  |  | 67,041 |
Reconciliation of segment net (loss) income |  |  |  |  |  |
Adjustments and reconciling items |  |  | — |  |  |  | — |
Consolidated net (loss) income |  | $ | (21,288 | ) |  | $ | 67,041 |
(1) Other segment (income) expense includes other research and development expense, amortization of debt issuance costs and discount, other income, warrant liabilities fair value adjustment, derivative liability fair value adjustment, and cost of product revenue.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration